4//SEC Filing
Vaughn James J 4
Accession 0001209191-19-049148
CIK 0001131324other
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 4:15 PM ET
Size
17.1 KB
Accession
0001209191-19-049148
Insider Transaction Report
Form 4
Vaughn James J
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2019-09-09$31.12/sh+3,000$93,360→ 19,417 total - Sale
Common Stock
2019-09-09$72.08/sh−3,000$216,230→ 17,917 total - Sale
Common Stock
2019-09-09$74.13/sh−200$14,826→ 16,417 total - Exercise/Conversion
Employee Stock Option (right to buy) Holding
2019-09-09−1,500→ 44,207 totalExercise: $33.21Exp: 2028-01-31→ Common Stock (1,500 underlying) - Exercise/Conversion
Employee Stock Option (right to buy) Holding
2019-09-09−3,000→ 0 totalExercise: $31.12Exp: 2025-02-13→ Common Stock (3,000 underlying) - Exercise/Conversion
Common Stock
2019-09-09$33.21/sh+1,500$49,815→ 20,917 total - Sale
Common Stock
2019-09-09$73.24/sh−1,300$95,213→ 16,617 total
Footnotes (9)
- [F1]Includes an aggregate of 11,281 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- [F2]These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 6, 2018.
- [F3]Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- [F4]Represents weighted average sale price. Actual sale prices ranged from $71.69 to $72.62.
- [F5]These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 11, 2019.
- [F6]Represents weighted average sale price. Actual sale prices ranged from $72.62 to $73.57.
- [F7]Represents weighted average sale price. Actual sale prices ranged from $73.96 to $74.30.
- [F8]The option became exercisable as to 25% of the shares on February 13, 2016, and became exercisable as to 1/48th of the shares each full month thereafter.
- [F9]The option became exercisable as to 25% of the shares on January 31, 2019, and becomes exercisable as to 1/48th of the shares each full month thereafter.
Documents
Issuer
GENOMIC HEALTH INC
CIK 0001131324
Entity typeother
Related Parties
1- filerCIK 0001649689
Filing Metadata
- Form type
- 4
- Filed
- Sep 10, 8:00 PM ET
- Accepted
- Sep 11, 4:15 PM ET
- Size
- 17.1 KB